Literature DB >> 23512735

Modeling metabolic syndrome through structural equations of metabolic traits, comorbid diseases, and GWAS variants.

Rebekah Karns1, Paul Succop, Ge Zhang, Guangyun Sun, Subba R Indugula, Dubravka Havas-Augustin, Natalija Novokmet, Zijad Durakovic, Sanja Music Milanovic, Sasa Missoni, Silvije Vuletic, Ranajit Chakraborty, Pavao Rudan, Ranjan Deka.   

Abstract

OBJECTIVE: To provide a quantitative map of relationships between metabolic traits, genome-wide association studies (GWAS) variants, metabolic syndrome (MetS), and metabolic diseases through factor analysis and structural equation modeling (SEM). DESIGN AND METHODS: Cross-sectional data were collected on 1,300 individuals from an eastern Adriatic Croatian island, including 14 anthropometric and biochemical traits, and diagnoses of type 2 diabetes, coronary heart disease, gout, kidney disease, and stroke. MetS was defined based on Adult Treatment Panel III criteria. Forty widely replicated GWAS variants were genotyped. Correlated quantitative traits were reduced through factor analysis; relationships between factors, genetic variants, MetS, and metabolic diseases were determined through SEM.
RESULTS: MetS was associated with obesity (P < 0.0001), dyslipidemia (P < 0.0001), glycated hemoglobin (HbA1c; P = 0.0013), hypertension (P < 0.0001), and hyperuricemia (P < 0.0001). Of metabolic diseases, MetS was associated with gout (P = 0.024), coronary heart disease was associated with HbA1c (P < 0.0001), and type 2 diabetes was associated with HbA1c (P < 0.0001) and obesity (P = 0.008). Eleven GWAS variants predicted metabolic variables, MetS, and metabolic diseases. Notably, rs7100623 in HHEX/IDE was associated with HbA1c (β = 0.03; P < 0.0001) and type 2 diabetes (β = 0.326; P = 0.0002), underscoring substantial impact on glucose control.
CONCLUSIONS: Although MetS was associated with obesity, dyslipidemia, glucose control, hypertension, and hyperuricemia, limited ability of MetS to indicate metabolic disease risk is suggested.
Copyright © 2013 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23512735     DOI: 10.1002/oby.20445

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  6 in total

1.  Analysis of risk factors of metabolic syndrome using a structural equation model: a cohort study.

Authors:  Zhimin Ma; Ditian Li; Siyan Zhan; Feng Sun; Chaonan Xu; Yunfeng Wang; Xinghua Yang
Journal:  Endocrine       Date:  2018-08-21       Impact factor: 3.633

2.  Multi-trait multi-locus SEM model discriminates SNPs of different effects.

Authors:  Anna A Igolkina; Georgy Meshcheryakov; Maria V Gretsova; Sergey V Nuzhdin; Maria G Samsonova
Journal:  BMC Genomics       Date:  2020-07-28       Impact factor: 3.969

3.  Structural equation modeling for hypertension and type 2 diabetes based on multiple SNPs and multiple phenotypes.

Authors:  Saebom Jeon; Ji-Yeon Shin; Jaeyong Yee; Taesung Park; Mira Park
Journal:  PLoS One       Date:  2019-09-12       Impact factor: 3.240

4.  Factor Analysis of Metabolic Syndrome Components in a Population-Based Study in the South of Iran (PERSIAN Kharameh Cohort Study).

Authors:  Hossein-Ali Nikbakht; Abbas Rezaianzadeh; Mozhgan Seif; Haleh Ghaem
Journal:  Iran J Public Health       Date:  2021-09       Impact factor: 1.429

5.  Association of DNA Methylation at CPT1A Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study.

Authors:  Mithun Das; Jin Sha; Bertha Hidalgo; Stella Aslibekyan; Anh N Do; Degui Zhi; Dianjianyi Sun; Tao Zhang; Shengxu Li; Wei Chen; Sathanur R Srinivasan; Hemant K Tiwari; Devin Absher; Jose M Ordovas; Gerald S Berenson; Donna K Arnett; Marguerite R Irvin
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

6.  Factor Analysis of Metabolic Syndrome Components in an Iranian Non-Diabetic Adult Population: A Population-Based Study from the North of Iran.

Authors:  Karimollah Hajian-Tilaki
Journal:  Int J Endocrinol Metab       Date:  2018-04-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.